Tandem Diabetes Care (NASDAQ:TNDM) had its price objective lifted by analysts at Cowen from $70.00 to $85.00 in a note issued to investors on Thursday, The Fly reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. Cowen’s target price would suggest a potential downside of 1.20% from the stock’s current price.
A number of other research firms have also recently commented on TNDM. Raymond James initiated coverage on Tandem Diabetes Care in a research note on Wednesday, February 5th. They set an “outperform” rating and a $85.00 target price on the stock. Robert W. Baird lowered Tandem Diabetes Care from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $71.00 to $75.00 in a report on Tuesday, February 4th. ValuEngine raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. Guggenheim started coverage on Tandem Diabetes Care in a report on Thursday, October 17th. They issued a “buy” rating and a $76.00 price objective for the company. Finally, BidaskClub raised Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $79.79.
NASDAQ TNDM opened at $86.03 on Thursday. The stock has a market capitalization of $5.08 billion, a price-to-earnings ratio of -172.06 and a beta of 0.08. Tandem Diabetes Care has a one year low of $47.36 and a one year high of $87.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.46 and a quick ratio of 2.05. The business’s fifty day moving average is $69.23 and its 200-day moving average is $64.48.
Hedge funds have recently bought and sold shares of the business. CWM LLC grew its holdings in Tandem Diabetes Care by 393.5% during the 4th quarter. CWM LLC now owns 528 shares of the medical device company’s stock valued at $31,000 after buying an additional 421 shares in the last quarter. First Quadrant L P CA purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at about $34,000. TRUE Private Wealth Advisors purchased a new position in Tandem Diabetes Care during the 4th quarter valued at about $45,000. Sowell Financial Services LLC purchased a new position in Tandem Diabetes Care during the 4th quarter valued at about $54,000. Finally, US Bancorp DE grew its holdings in Tandem Diabetes Care by 101.0% during the 4th quarter. US Bancorp DE now owns 1,164 shares of the medical device company’s stock valued at $70,000 after buying an additional 585 shares in the last quarter. 82.96% of the stock is owned by institutional investors and hedge funds.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Recommended Story: Why is the price-sales ratio important?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.